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butilide Added to Propafenone for the
onversion of Atrial Fibrillation and Atrial Flutter
ohn A. Chiladakis, MD, FESC, Andreas Kalogeropoulos, MD, Nikolaos Patsouras, MD,
ntonis S. Manolis, MD, FACC, FESC
atras and Athens, Greece
OBJECTIVES We evaluated the safety and efficacy of ibutilide when added to propafenone in treating both
paroxysmal and chronic atrial fibrillation (AF) and atrial flutter (AFL).
BACKGROUND The effects of ibutilide in patients with paroxysmal or chronic AF/AFL who were pre-treated
with propafenone have not been previously evaluated.
METHODS Oral propafenone was initially given in 202 patients with AF/AFL without left ventricular
dysfunction. Intravenous ibutilide was administered in 104 patients in whom propafenone
failed to convert the arrhythmia. Two different propafenone dosage regimens were used
according to the duration of the presenting arrhythmia: patients with paroxysmal arrhythmia
(n  48) received 600 mg loading dose, and patients with chronic arrhythmia (n  56) were
receiving 150 mg three times a day as stable-dose pre-treatment.
RESULTS Ibutilide offered an overall conversion efficacy of 66.3% (69 of 104 patients), 70.8% for
patients with paroxysmal AF/AFL and 62.5% for patients with chronic AF/AFL. Ibutilide
significantly decreased the heart rate (HR) and further prolonged the QTc interval (p 
0.0001). The degree of HR reduction after ibutilide administration emerged as the sole
predictor of successful arrhythmia termination (p  0.001). After ibutilide, one patient (1%)
developed two asymptomatic episodes of non-sustained torsade de pointes, and 10 patients
(9.6%) manifested transient bradyarrhythmic events; however, all bradyarrhythmic effects
were predictable, occurring mostly at the time of arrhythmia termination. None of 82 patients
who decided to continue propafenone after successful cardioversion had immediate arrhyth-
mia recurrence.
CONCLUSIONS Our graded approach using propafenone and ibutilide appears to be a relatively safe and
effective alternative for the treatment of paroxysmal and chronic AF/AFL to both rapidly
restore sinus rhythm in nonresponders to monotherapy with propafenone and prevent
immediate recurrences of the arrhythmia. (J Am Coll Cardiol 2004;44:859–63) © 2004 by
the American College of Cardiology Foundatione
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eanaging atrial fibrillation (AF) or atrial flutter (AFL) is a
ontinuing therapeutic challenge. Antiarrhythmic drugs
lay a major role during attempts to promptly restore and
aintain sinus rhythm (SR), by which disabling symptoms
re diminished and atrial electrophysiologic and structural
emodeling is averted (1,2). Of the currently available
gents, intravenous ibutilide fumarate is considered one of
he most effective in rapidly terminating AF/AFL (3–6).
owever, ibutilide is not available as an oral preparation,
nd thus, it cannot be subsequently used as long-term
herapy to prevent recurrences of arrhythmia. On the other
and, the use of oral propafenone has been proven effective
n terminating AF of recent onset and in preventing
rrhythmia recurrences after cardioversion, but it has shown
ittle promise for the conversion of chronic AF (7–9). We
ypothesized that the addition of ibutilide in nonresponders
o monotherapy with propafenone might be a useful method
o improve subsequent cardioversion rates and maintenance
f SR thereafter. This study evaluated the safety and clinical
From the Cardiology Department, Patras University Hospital, Rio, Patras, Greece.
Manuscript received February 1, 2004; revised manuscript received April 12, 2004,pccepted April 18, 2004.fficacy of this stepped-care combination therapy in the
anagement of both paroxysmal and chronic AF/AFL.
ETHODS
atient population. Our study population included 202
atients with AF/AFL who were treated initially with
ropafenone. Two groups of patients were prospectively
tudied; those with persistent paroxysms of arrhythmia and
atients with chronic arrhythmia. Patients with paroxysmal
F/AFL (n  146) had prolonged and non-self-
erminating arrhythmia episodes of 36 h duration with a
ell-defined clinical history of abrupt onset of palpitations
nd electrocardiographic (ECG) evidence of the arrhyth-
ia. Patients with chronic AF/AFL (n 56) had persistent
rrhythmia of 6-month duration and were under contin-
ous oral anticoagulation therapy for at least four weeks
efore cardioversion (international normalized ratio, 2.5 to
.0). Only patients with normal left ventricular (LV) func-
ion as judged by two-dimensional echocardiography were
nrolled in this trial.
Ibutilide in addition to propafenone was given to 104
atients who did not convert to SR with propafenone, in 48
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ith chronic arrhythmia.
The following exclusion criteria were applied: symptoms
r clinical signs of congestive heart failure and unstable
ngina; prior myocardial infarction; obstructive pulmonary
isease; depressed LV ejection fraction; severe valvular
ysfunction; significant hepatic, renal, or metabolic distur-
ances; known dysthyroidism; alcohol intake; known sick
inus syndrome; major atrioventricular and intraventricular
onduction disturbances; ventricular preexcitation and his-
ory of torsade de pointes; concomitant use of other antiar-
hythmic drugs or beta-adrenergic blocking agents; pace-
aker dependence; and pregnancy. All patients had serum
lectrolyte values within normal limits before treatment.
butilide was not administered if propafenone prolonged the
RS or the corrected QT (QTc) interval by 25%.
harmacologic therapy and ECG analysis. Ventricular
ate control in patients with paroxysmal arrhythmia was
ttempted, whenever necessary, with intravenous diltiazem,
dministered initially as a bolus of 25 mg over 15 min,
ollowed by continuous infusion of 10 mg/h to achieve a
arget resting heart rate (HR) 100 beats/min. In addition,
eparin was administered upon admission with a bolus of
,000 IU followed by infusion of 1,000 IU/h, further
djusted as required to keep the activated partial thrombo-
lastin time at twice the upper normal limit. In patients
ith chronic AF/AFL, the use of oral diltiazem 90 mg three
imes a day was allowed.
Propafenone therapy was initiated in patients with par-
xysmal AF/AFL as an oral loading dose of 600 mg, and if
R was not restored after 6 h, a second single dose of 150
g was repeated. In case of restoration of SR in the
mergency department, patients were not admitted to the
ospital, and possible pharmacologic therapy was left to the
iscretion of the treating physician. Patients with non-
onverted paroxysmal AF/AFL at the end of an 8-h initial
bservation period proceeded to the treatment phase with
butilide. Most patients with chronic AF/AFL were asymp-
omatic (41 of 56, 73%) under continuous propafenone
herapy with or without diltiazem, and 7 (8%) of them had
rior failed conversion attempts with quinidine, but they all
ought further treatment to restore SR. Thus, all patients
ith chronic AF/AFL were referred for elective cardiover-
ion after they had initially been administered oral
ropafenone as outpatients, receiving 150 mg three times a
Abbreviations and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
ECG  electrocardiogram/electrocardiographic
HR  heart rate
LV  left ventricle/ventricular
QTc  corrected QT (interval)
SR  sinus rhythmay for a minimum of four days before admission to the sospital. This dose of propafenone remained the same
hroughout hospitalization, when indicated, to assist in
aintaining SR once the arrhythmia had been converted
ith ibutilide.
Ibutilide was administered to all patients with paroxysmal
nd chronic arrhythmia in the coronary care unit under
ontinuous monitoring at the same dose of 1 mg over 10
in intravenously, and if the arrhythmia was still present
fter 10 min, an additional dose of 1 mg over 10 min was
nfused. Drug infusion was terminated in case of any change
n symptoms or rhythm or any adverse event that in the
pinion of the investigator was threatening patient’s safety.
atients were monitored for at least 12 h after the admin-
stration of ibutilide. Successful cardioversion was defined as
ermination of AF/AFL within 90 min of the start of the
rst ibutilide infusion. Electrical transthoracic direct-
urrent cardioversion was attempted after a 4-h observation
eriod if AF/AFL was not converted to SR.
Serial 12-lead ECGs were obtained to evaluate QRS,
T, and QTc intervals. A 24-h Holter recording was
tarted in all patients before the onset of ibutilide adminis-
ration to determine exact conversion time, arrhythmia, and
R analysis. The three-channel Galix MA-3C Holter
ystem (Galix Biomedical Instrumentation Inc., Miami
each, Florida) was used, utilizing 3.0 Software. The
ollowing time periods were taken to assess the effects of the
rugs on the ECG variables: for propafenone, the last
-min period before the initiation of the first ibutilide
nfusion; for ibutilide, the last 5-min period before arrhyth-
ia termination if it was converted to SR or the first 5-min
nterval at the end of the second ibutilide infusion if the
rrhythmia was not terminated.
tatistics. Continuous variables are reported as mean 
D. A value of p  0.05 was considered statistically
ignificant. The two-sided unpaired Student t test was used
o compare normally distributed continuous data between
onversion and non-conversion groups. Normality was
ested by the Kolmogorov-Smirnov statistic at the p  0.1
evel. Changes in continuous ECG variables within groups
efore and after ibutilide treatment were evaluated using the
aired t test. Categorical data were compared with Fisher
xact test. Multiple logistic regression models with a for-
ard stepwise approach were used to identify significant
redictors of conversion. Statistical analyses were conducted
ith SPSS-PC, Version 10.0 (SPSS Inc., Chicago, Illinois).
ESULTS
onversion to SR. Oral loading propafenone restored SR
n 98 of 146 patients (67%) with paroxysmal arrhythmia.
butilide was evaluated in 104 hospitalized patients with
F/AFL: in the remaining 48 non-converters with parox-
smal arrhythmia and in the 56 patients with chronic
rrhythmia receiving pre-treatment with propafenone (Ta-
le 1). Overall, the co-administration of the two agents
howed a conversion efficacy of 66.3% (69 of 104 patients),
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August 18, 2004:859–63 Ibutilide and Propafenone for AF5.6% for AF (63 of 96 patients), and 75% (6 of 8 patients)
or AFL. The success rates were 70.8% (34 of 48 patients)
or patients with paroxysmal arrhythmia and 62.5% (35 of
6 patients) for those with chronic arrhythmia (Table 2).
ddition of ibutilide. Among the entire study population,
ompared with the effects of propafenone (paired t test),
butilide significantly decreased the mean HR (from 81.1 
4.3 to 74.6  14.5; p  0.0001), increased the QT (from
82.3  43.9 to 459.6  53.7; p  0.0001) and the QTc
nterval (from 443.1  49.2 to 515.6  43.6; p  0.0001),
nd did not significantly change the QRS width (from 100.1
11.4 to 103.3  10.1; p  0.3). The mean time to
ermination of AF/AFL from the beginning of ibutilide
nfusion was 38.9  22.5 min (36.4  23.8 min for
aroxysmal and 36.4  24.7 min for chronic arrhythmia; p
0.5). Between converted and non-converted patients
unpaired t test), there were no statistically significant
ifferences in demographics and clinical data (Table 2).
owever, ibutilide converters had significantly higher HRs
77.9  15.6 vs. 68.8  10.2; p  0.001) and lesser
Table 1. Clinical Characteristics of Study Patie
Age (yrs)
Men, n (%)
Atrial flutter, n (%)
Duration of AF/AFL
Previous history of AF/AFL, n (%)
Cardiovascular history, n (%)
Minor valvular disease
Coronary artery disease
Systemic hypertension
Left atrial diameter, mm
Concomitant drug therapy, n (%)
Diltiazem
Digoxin
ECG variables before treatment
Mean ventricular rate (beats/min)
QTc (ms)
AF/AFL  atrial fibrillation/atrial flutter; ECG  electroca
able 2. Determinants of Conversion in 104 Patients With AF/A
Paroxysmal AF/AFL
Conversion
(n  34)
No Con
(n 
ge (yrs) 60.7  10.2 59.9 
en, n (%) 25 (74) 13 (
uration of arrhythmia 77.7  47.6 h 72.9 
ardiovascular history, n (%) 10 (21) 7 (1
eft atrial diameter, mm 43.4  7 41.2 
ropafenone
Mean ventricular rate (beats/min) 83.3 15.2 88.2 
QT (ms) 380.3  59.1 381.6 
QTc (ms) 446.5  54.1 473.2 
butilide added to propafenone
Mean ventricular rate (beats/min) 79.8 16.5 76.5 
QT (ms) 458.1  78.3 472.1 
QTc (ms) 531.0  58.1 539.1 F/AFL  atrial fibrillation/atrial flutter.rolongation of the QT interval (451.8  60.5 vs. 472.6 
7.6; p  0.04) than non-converters. On multiple logistic
egression analysis, which evaluated age, gender, type of
rrhythmia, onset of arrhythmia (paroxysmal or chronic),
eft atrium size, HR, QT and QTc intervals, and QRS
idth, only the difference in mean HR after ibutilide was
ound to independently predict conversion to SR (p 
.001). There was an inverse relation between the degree of
R reduction after ibutilide with the conversion success
i.e., patients who exhibited higher HR reduction had lower
robability of conversion) (Table 2).
Thirty-three patients who did not convert with ibutilide
onsented to electrical cardioversion, which was successful
n 32 (97%) of 33 patients. None of the overall 82 patients
ho decided to continue propafenone therapy after success-
ul cardioversion had immediate arrhythmia recurrence
hroughout their hospital stay (mean, 23.5  5.9 h).
lectrocardiographic effects of ibutilide. We chose to
eparately analyze the effects of ibutilide in 49 patients with
hronic AF who received long-term stable dosages of
reated With Ibutilide and Propafenone
ysmal AF/AFL
(n  48)
Chronic AF/AFL
(n  56)
0.5  11.2 63.7  8.2
38 (79) 32 (57)
4 (8) 4 (7)
7.3  7.6 h 64.6  44.1 days
16 (33) 22 (39)
17 (35) 26 (46)
9 (19) 15 (27)
3 (6) 5 (9)
5 (10) 6 (11)
4.8  6.2 4.4  5.5
45 (94) 19 (34)
7 (15) 4 (7)
124  23 80.6  13.9
78.9  26.6 435.6  36.9
aphic.
Treated With Ibutilide and Propafenone
48) Chronic AF/AFL (n  56)
n
p
Conversion
(n  35)
No Conversion
(n  21) p
0.8 63.4  8.6 64.2  7.7 0.7
0.5 22 (63) 10 (48) 0.3
h 0.7 16.3  7.3 days 15.4  8.0 days 0.7
0.2 15 (27) 11 (20) 0.6
0.2 43.4  5.2 45.1  5.9 0.3
0.3 79.0  15.7 73.0  10.3 0.1
0.6 383.5  35.7 378.2  33.1 0.6
0.1 441.2  32.3 424.3  48.2 0.1
0.5 76.5  14.3 64.8  9.8 0.002
0.5 450.7  46.6 470  40.4 0.1
0.6 509.3  38.6 499.7  35.8 0.3nts T
Parox
6
1
3FL
(n 
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Ibutilide and Propafenone for AF August 18, 2004:859–63ropafenone with or without diltiazem assuming that the
ndings before and after ibutilide treatment would be
ntirely due to the additional effects of ibutilide. In these
atients ibutilide significantly decreased the HR from 74.6
9.7 to 70.3  11.1 (p  0.0001) and increased the QT
nterval from 381.7  33.4 to 461.5  44.6 (p  0.0001)
nd the QTc interval from 428.1  32.9 to 502.8  37.8
p  0.0001) (paired t test).
dverse effects. Propafenone treatment was discontinued
n 3 (4.3%) of 69 patients after restoration of SR following
butilide: in two patients due to dizziness and nausea and in
ne patient due to persistence of second-degree atrioven-
ricular block type I. None of the patients necessitated
nterruption of ibutilide treatment due to acute untoward
ffects. After ibutilide administration and immediately be-
ore reversion of AF to SR, four patients were documented
o have asymptomatic pauses (3.7 to 5.2 s), four patients had
ransient junctional rhythm for a mean of 7.5 6 s, and two
atients with chronic AF developed second degree atrioven-
ricular block type I. None of these patients required
nsertion of a temporary pacemaker. There were two asymp-
omatic self-terminating episodes of torsade de pointes (15
nd 8 QRS complexes, respectively) following ibutilide in
ne patient with chronic AF 5 min after conversion to SR.
uring ibutilide infusion, transient asymptomatic ventricu-
ar arrhythmias not requiring intervention were noted in
hree patients with chronic AF: one patient developed
on-sustained runs of ventricular tachycardia of three con-
ecutive beats, and two others had frequent premature
entricular complexes.
ISCUSSION
o our knowledge, this is the first study evaluating the
ffects of ibutilide in patients with both paroxysmal and
hronic AF/AFL who were pre-treated with propafenone,
hich demonstrates the combined strength in improving
harmacologic conversion rates with a low risk of proar-
hythmia and low probability of immediate arrhythmia
ecurrences.
ffects of propafenone. Our results of 67% efficacy of a
ingle oral loading dose of 600 mg propafenone in convert-
ng paroxysmal AF are consistent with the 56% to 87%
uccess rates within 8 h reported in other studies, confirm-
ng a higher conversion ability compared with both placebo
nd drugs that control the ventricular rate (10–12). The
idely variable interindividual pharmacokinetics of the drug
nd the lack of significant correlation between plasma
oncentrations and its antiarrhythmic efficacy may account
or the usefulness of this convenient oral loading approach
n clinical practice (13,14).
ddition of ibutilide. Ibutilide’s antifibrillatory actions
esult from its ability to prolong action potential duration
nd atrial effective refractory period predominantly by acti-
ating the sodium component of the plateau inward current
nd by blocking the rapid component of the delayed rectifier rotassium current. In contrast with propafenone, ibutilide is
evoid of beta-blocking effects, causes mild slowing of sinus
ate and atrioventricular conduction, while having no sig-
ificant effect on contractility (15,16). As a general consid-
ration, the possible enhanced antiarrhythmic efficacy by
dding ibutilide to propafenone may be primarily related to
verlapping effects on the action potential duration and
articularly on the prolongation of the atrial effective refrac-
ory period.
In previous studies, ibutilide monotherapy was found
uperior to placebo in terminating 35.0% to 70.6% of
atients with AF and 58% to 75% of patients with AFL,
hereby a short duration of the arrhythmia emerged as the
ain predictor of arrhythmia termination (3–6). In the
resent study, we demonstrated that the initial conversion
fficacy of oral loading propafenone in patients with parox-
smal arrhythmia was 67% (98 of 146 patients). In the
emaining 48 non-converters, ibutilide was successful in 34
atients (71%). Thus, the addition of ibutilide offered an
dditive conversion effect of approximately 23%, increasing
he overall efficacy of the combination therapy up to 90%.
or the patients with chronic arrhythmia of 6 months
uration, the success rate of 64% should be given particular
onsideration if we keep in mind that all patients were
onresponders to propafenone and that all previous studies
mphasize ibutilide’s efficacy in patients with AF of shorter
uration lasting approximately 3 months (3–6). More-
ver, it should be emphasized that our stepped-care ap-
roach of management prevented immediate recurrences; all
uccessfully converted patients maintained SR during their
hort hospital stay (median, 24 h). This was not surprising
ecause previous studies have shown that propafenone is
ffective in preventing immediate re-initiation of arrhyth-
ia after the cardioversion procedure (17).
afety. In contrast with the overall incidence of 4.3% of
olymorphic ventricular tachycardia in ibutilide-treated pa-
ients reported in clinical trials, including 1.7% of patients in
hom the arrhythmia was sustained and required cardio-
ersion (15), only 1% of our study patients developed
elf-terminating episodes of torsade de pointes. The strict
xclusion of patients with depressed LV function may be the
ain reason for this low incidence of proarrhythmia. Other
otentially worrisome cardiac side effects manifested as
inus pauses and atrioventricular conduction disturbances in
.6% of our study patients after instituting ibutilide therapy.
owever, all minor bradyarrhythmic effects were predict-
ble, occurring within the first hours after the addition of
butilide, mostly at the time of arrhythmia termination.
tudy limitations. The low risk of proarrhythmia of our
tudy population should not be extrapolated to patients with
epressed LV ejection function. It is important to note that
revious studies that have included patients with LV dys-
unction and valvular heart disease have expressed concerns
ver a higher incidence of torsade de pointes after ibutilide
3,4). Besides, due to the lack of a patient group who
eceived ibutilide monotherapy, we cannot compare the
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August 18, 2004:859–63 Ibutilide and Propafenone for AFroarrhythmia risk and the net ECG effects of our combi-
ation therapy with ibutilide alone. Another limitation of
his study is the different propafenone dosing regimens
sed, based on the methodologic scheme in which the
atients were enrolled.
onclusions. Our proposed stepped-care pharmacologic
pproach by first using propafenone and then ibutilide to
hose who do not respond to propafenone appears to be a
ational alternative for both rapidly terminating and pre-
enting immediate recurrences of paroxysmal and chronic
F/AFL. This drug combination may limit ibutilide’s
roarrhythmic response in patients with preserved LV
jection fraction. Ibutilide added to propafenone shows an
dditive efficacy up to 23% in arrhythmia conversion in
atients with paroxysmal AF/AFL and up to 62.5% in
atients with chronic arrhythmia who did not respond to
ropafenone.
eprint requests and correspondence: Dr. Antonis S. Manolis,
ardiology Department, 41 Kourempana Street, Agios Dimitrios
73 43, Athens, Greece. E-mail: asm@otenet.gr.
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